BPL-003 (mebufotenin benzoate) vs Psilocybin (COMP360)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
BPL-003 (mebufotenin benzoate)
Developed by AtaiBeckley Inc. and partners
NCT05870540 · Phase 2 · completed
The core study randomized 196 participants and used a masked design with an active-placebo comparator; its primary endpoint was the clinical depression measure MADRS. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: November 2026 · NCT05660642 (registry estimate)
Reported efficacy
Change from baseline in Montgomery-Asberg Depression Rating Scale (MADRS) (4 weeks): MADRS change from baseline at Day 29: 12 mg BPL-003 -11.1 points vs -5.8 points for 0.3 mg comparator arm (p=0.0038); 8 mg BPL-003 -12.1 points vs 0.3 mg comparator (p=0.0025). (met)
Result source: NCT05870540
Psilocybin (COMP360)
Developed by COMPASS Pathways
NCT05711940 · Phase 3 · active, not recruiting
This was a randomized, quadruple-blinded, active-comparator-controlled trial with a large sample size (572 participants) and a primary endpoint (MADRS depression score change) that is a validated, hard clinical measure of disease severity, not a lab biomarker. The primary comparison between the high dose and low-dose control arm reached statistical significance in the favorable direction (p<0.001), meeting the design's own pre-specified success criteria.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2029 · NCT06132178 (registry estimate)
Reported efficacy
COMP360 25 mg versus COMP360 1 mg for the change from baseline in MADRS total score. (Week 6): COMP006 (NCT05711940), primary endpoint MADRS change at week 6: COMP360 25 mg vs 1 mg difference -3.8 points; p<0.001. (met)
Result source: NCT05711940
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | BPL-003 (mebufotenin benzoate) | Psilocybin (COMP360) |
|---|---|---|
| MADRS, change (acute) | -11.1 vs -5.8avs 0.3 mg comparator armNCT058705401 other result
| -12 vs -6.8−5.2 vs placeboNCT03775200 |
| CGI-S, change (acute) | —Not reported | —Not posted · NCT05624268 |
| MADRS response | —Not reported | —Not posted · NCT05624268 |
| MADRS remission | —Not reported | —Not posted · NCT05624268 |
| Relapse (% of patients) | —Not reported | —Not posted · NCT05624268 |
MADRS, change (acute)
- BPL-003 (mebufotenin benzoate)
- -11.1 vs -5.8avs 0.3 mg comparator armNCT05870540
1 other result
- -12.1 vs -5.8 NCT05870540
- Psilocybin (COMP360)
- -12 vs -6.8−5.2 vs placeboNCT03775200
CGI-S, change (acute)
- BPL-003 (mebufotenin benzoate)
- —Not reported
- Psilocybin (COMP360)
- —Not posted · NCT05624268
MADRS response
- BPL-003 (mebufotenin benzoate)
- —Not reported
- Psilocybin (COMP360)
- —Not posted · NCT05624268
MADRS remission
- BPL-003 (mebufotenin benzoate)
- —Not reported
- Psilocybin (COMP360)
- —Not posted · NCT05624268
Relapse (% of patients)
- BPL-003 (mebufotenin benzoate)
- —Not reported
- Psilocybin (COMP360)
- —Not posted · NCT05624268
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. BPL-003 (mebufotenin benzoate): 0 of 4 rows · Psilocybin (COMP360): 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | BPL-003 (mebufotenin benzoate) | Psilocybin (COMP360) |
|---|---|---|
| Dropout rate | — | 0%25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result6.3%25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | — | —25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result—25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Serious AEs | — | 0%25 mga NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result6.3%25 mg NCT03775200 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | — | 25 mga headache 31.6% blood pressure increased 15.8% depression 5.3% NCT04739865 · Phase 2 · registry result, not featured evidence show 1 more result25 mg headache 34.2% (placebo 25.3%) nausea 22.8% (placebo 5.1%) fatigue 15.2% (placebo 8.9%) NCT03775200 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Psilocybin (COMP360)
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BPL-003 (mebufotenin benzoate)'s landscape · Psilocybin (COMP360)'s landscape